WO2010135431A3 - Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma) - Google Patents

Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma) Download PDF

Info

Publication number
WO2010135431A3
WO2010135431A3 PCT/US2010/035410 US2010035410W WO2010135431A3 WO 2010135431 A3 WO2010135431 A3 WO 2010135431A3 US 2010035410 W US2010035410 W US 2010035410W WO 2010135431 A3 WO2010135431 A3 WO 2010135431A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
prostate
devices
specific membrane
membrane antigen
Prior art date
Application number
PCT/US2010/035410
Other languages
English (en)
Other versions
WO2010135431A2 (fr
Inventor
Gregory A. Weiss
Jessica Arter
Juan E. Diaz
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to US13/321,011 priority Critical patent/US8986655B2/en
Publication of WO2010135431A2 publication Critical patent/WO2010135431A2/fr
Publication of WO2010135431A3 publication Critical patent/WO2010135431A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des ligands à PSMA, des compositions, et des procédés selon lesquels le ligand est un peptide ayant la séquence X1X2CVEVX3QNSCX4X5 où X1-X5 sont indépendamment un acide aminé naturel ou non naturel ou un peptide ayant la séquence CALCEFLG [SEQ ID n° : 1]. Les aspects particulièrement préférés comprennent des réactifs diagnostiques pour la détection et/ou la quantification de PSMA dans un échantillon, des réactifs thérapeutiques, et des réactifs d'imagerie diagnostiques.
PCT/US2010/035410 2009-05-19 2010-05-19 Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma) WO2010135431A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/321,011 US8986655B2 (en) 2009-05-19 2010-05-19 Compositions, devices, and methods related to prostate-specific membrane antigen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17944109P 2009-05-19 2009-05-19
US61/179,441 2009-05-19
US61/179,609 2009-05-19

Publications (2)

Publication Number Publication Date
WO2010135431A2 WO2010135431A2 (fr) 2010-11-25
WO2010135431A3 true WO2010135431A3 (fr) 2011-01-13

Family

ID=43479582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/035410 WO2010135431A2 (fr) 2009-05-19 2010-05-19 Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma)

Country Status (1)

Country Link
WO (1) WO2010135431A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103048473B (zh) * 2012-12-18 2015-05-13 苏州浩欧博生物医药有限公司 一种促卵泡生成激素的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法
CN103048461A (zh) * 2012-12-18 2013-04-17 苏州浩欧博生物医药有限公司 一种癌抗原ca15-3的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法
WO2016149404A1 (fr) 2015-03-16 2016-09-22 California Institute Of Technology Agents de capture spécifiques de la neurotoxine botulique, compositions et méthodes d'utilisation et de préparation associées
EP3519425B1 (fr) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions pour la détection, l'inhibition et l'imagerie de l'indoléamine 2,3-dioxygénase 1 (ido1) et leurs méthodes de production et d'utilisation
EP3571221A2 (fr) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
EP3638687A1 (fr) 2017-06-15 2020-04-22 Indi Molecular, Inc. Agents de capture spécifiques d'il-17f et il-17a, compositions et procédés d'utilisation et de production
JOP20200135A1 (ar) * 2017-12-11 2020-06-02 Univ Muenchen Tech مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
WO2022098743A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020278A1 (en) * 2004-01-09 2007-01-25 Millennium Pharmaceuticals, Inc.*Ewc* Diagnosing and treating cancer
US20080081768A1 (en) * 2006-02-20 2008-04-03 Watt Paul M Methods of constructing and screening libraries of peptide structures
US20090092965A1 (en) * 2006-03-09 2009-04-09 The Regents Of The University Of California Method and Apparatus for Target Detection Using Electrode-Bound Viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020278A1 (en) * 2004-01-09 2007-01-25 Millennium Pharmaceuticals, Inc.*Ewc* Diagnosing and treating cancer
US20080081768A1 (en) * 2006-02-20 2008-04-03 Watt Paul M Methods of constructing and screening libraries of peptide structures
US20090092965A1 (en) * 2006-03-09 2009-04-09 The Regents Of The University Of California Method and Apparatus for Target Detection Using Electrode-Bound Viruses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSSON ET AL: "Pseudogenes, junk DNA, and the dynamics of Rickettsia genomes", MOL. BIOL. EVOL., vol. 18, 2001, pages 829 - 839 *
DATABASE UNIPROT [online] 3 April 2007 (2007-04-03), WARD B. ET AL, retrieved from http://www.uniprot.org/uniprot/A3JDN2 accession no. EMBL Database accession no. A3JDN2 *
KANEKO ET AL: "Complete genomic structure of the bloom-forming toxic cyanobacterium Microcystis aeruginosa NIES-843", DNA RES., vol. 14, 2007, pages 247 - 256, XP055200990, DOI: doi:10.1093/dnares/dsm026 *
MATTHIJNSSENS ET AL: "Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains", J. VIROL., vol. 82, 2008, pages 3204 - 3219 *
MYERS ET AL: "Skewed genomic variability in strains of the toxigenic bacterial pathogen, Clostridium perfringens", GENOME RES., vol. 16, 2006, pages 1031 - 1040, XP002496207, DOI: doi:10.1101/gr.5238106 *

Also Published As

Publication number Publication date
WO2010135431A2 (fr) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2010135431A3 (fr) Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma)
WO2008005880A3 (fr) Anticorps anti-norovirus
WO2002092836A3 (fr) Sequence nucleotidique codant un antigene ovarien ca125 et ses utilisations
EP2202310A3 (fr) Ligands de chromatographie stables caustiques
WO2010037836A3 (fr) Anticorps monocaténaire bispécifique psmaxcd3, spécifique d'espèces croisées
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
ATE410178T1 (de) Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration
WO2011119934A3 (fr) Procédés et substances pour la détection de tumeurs colorectales
WO2005087811A3 (fr) Recepteurs des oestrogenes et procedes d'utilisation associes
EP2518155A3 (fr) Capteurs d'enzyme, procédés de préparation et utilisation de tels capteurs, et procédés de détection de l'activité protéase
WO2009004822A1 (fr) ANTICORPS ANTI-Muc17
EP3249405A3 (fr) Composition de stabilisation pour biomolécules immobilisées
EP2292644A3 (fr) Petits antigènes pyogènes streptococcus et leur utilisation
MXPA06008217A (es) Vacunas con subunidad de lawsonia intracellularis.
EP2670755A1 (fr) Réactifs de réticulation trifonctionnels
HK1117595A1 (en) Method for detecting autoimmune antibodies against tsh receptors and novel tsh-receptor chimaeras
WO2007087263A3 (fr) Citrate, zinc et zip1 humain destines au criblage d’un cancer de la prostate
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
EP2628750A3 (fr) Identification ciblée de peptides immunogènes
WO2004072223A3 (fr) Identification et caracterisation de racemases, definition de signatures proteiques, test de detection d'acide amine et de criblage de molecules pouvant inhiber l'activite d'une racemase, notamment de la racemase de proline
WO2006077101A3 (fr) Peptides de ptag et leur utilisation
WO2005072050A9 (fr) Nouvelles sequences nucleotidiques et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du sein
WO2009115508A3 (fr) Peptides luttant contre s. pneumoniae et compositions, méthodes et utilisations associées
JP2009524413A5 (fr)
EP1914320A3 (fr) Procédé pour la détection d'une ou plusieurs positions CpG

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778329

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13321011

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10778329

Country of ref document: EP

Kind code of ref document: A2